Who Paid My Doc
Sara Assaf
Pulmonary Disease Albuquerque, NM Medical Doctor
NPI 1396150397 CMS profile 7228326
1 University Of New Mexico # 105550, Albuquerque, NM 87131
General payments
$240
Research payments
$1,597
Ownership & investment interest
$0
Research they led as principal investigator
$33,458
Through program year 2025, Sara Assaf of Albuquerque, NM is reported in the CMS Open Payments database as having received $240 across 3 general payments and $1,597 in research payments paid to them. Separately, studies naming them as principal investigator received $33,458 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 50th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $24 | 1 | |
| 2023 | Research | $86 | 2 | |
| 2022 | Research | $1,511 | 7 | |
| 2020 | General | $91 | 1 | |
| 2019 | General | $125 | 1 |
Beside peers
- Sara Assaf
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Sara Assaf were reported at $24. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Sara Assaf | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $125 | $377 | $109–$1,340 | $163 |
| 2020 | $91 | $230 | $56–$907 | $114 |
| 2021 | $0 | $269 | $68–$1,072 | $132 |
| 2022 | $0 | $390 | $100–$1,457 | $149 |
| 2023 | $0 | $419 | $114–$1,659 | $160 |
| 2024 | $0 | $476 | $123–$1,818 | $164 |
| 2025 | $24 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
622
Drug cost
$244,913
Branded share of claims
93.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 96 | $45,259 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 54 | $43,833 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 68 | $43,384 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 72 | $20,468 | |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | Brand | 28 | $17,648 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 43 | $17,168 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 28 | $16,659 | |
| Spiriva Handihaler Tiotropium Bromide | Brand | 14 | $15,451 | |
| Breyna Budesonide/Formoterol Fumarate | Brand | 31 | $5,462 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 21 | $5,381 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 23 billing codesPaid by Medicare
$34,663
Medicare patients
189
Services billed
360
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| COPD | 46% | |
| Diabetes | 38% | |
| Depression | 32% | |
| Chronic kidney disease | 31% | |
| Ischemic heart disease | 29% | |
| Heart failure | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in New Mexico
Related records
Pulmonary Disease in New Mexico
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in New Mexico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.